Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Biotheus Signs $142 Million Deal for Alligator Bio TNFR Antibody

publication date: Aug 22, 2019

Biotheus, a China biopharma based in Zhuhai, Guangdong, announced a $142 million agreement to in-license greater China rights for a TNFR antibody developed by Alligator Bio of Stockholm. Formed in 2018, Biotheus will have rights for up to three bi-specific candidates based on the antibody. The agreement, which specifies a $1 million upfront payment, will include a $90 million option for Biotheus to acquire global rights to the candidates. Biotheus is developing a pipeline of me-better/novel candidates focused on immuno-oncology and metabolic disease. More details....

Stock Symbol: (NSDQ Stockholm: ATORX)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.